Dr Reddy's Laboratories reports quarterly profit beat despite consolidated net income decline
Dr Reddy's Laboratories reported a 12.1 billion rupee profit for the December quarter. Strong growth in India helped the company exceed analyst expectations.
Insights:
Dr. Reddy's Laboratories Ltd reported a consolidated net profit of 12.1 billion rupees for the quarter ended December 31, 2025, exceeding analyst expectations despite marking the company's first profit decline in five quarters. The 14.4% drop from the previous year was less severe than the 10.70 billion rupees estimated by analysts. This performance was supported by total revenue from operations rising 4.4% to 87.53 billion rupees, which also surpassed the consensus estimate of 84.17 billion rupees.
The quarterly results highlight a significant divergence between the company's geographic markets. Revenue from the business in IN 
INrose 19% to 16.03 billion rupees, bolstered by strategic acquisitions and new product entries. In September, Dr. Reddy's Laboratories Ltdacquired the Stugeron anti-vertigo brand from Johnson & Johnson . The company also strengthened its domestic gastrointestinal portfolio with two new launches last year and continued its 2024 partnership with Nestle India Limited to produce supplements and nutraceuticals.
INrose 19% to 16.03 billion rupees, bolstered by strategic acquisitions and new product entries. In September, Dr. Reddy's Laboratories Ltdacquired the Stugeron anti-vertigo brand from Johnson & Johnson . The company also strengthened its domestic gastrointestinal portfolio with two new launches last year and continued its 2024 partnership with Nestle India Limited to produce supplements and nutraceuticals.
